The dilemma of prostate-specific antigen testing

Archives of Internal Medicine

Volumn 172, Issue 11, 2012, Pages 835-836

  Leach, Robin ^a   Thompson, Ian M ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; CANCER GRADING; CANCER MORTALITY; DECISION MAKING; DIGITAL RECTAL EXAMINATION; DISEASE SURVEILLANCE; EDITORIAL; HUMAN; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RISK ASSESSMENT;

ADENOCARCINOMA; AGED; ANTIGENS, NEOPLASM; BIOPSY; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DECISION MAKING; DIGITAL RECTAL EXAMINATION; DISEASE PROGRESSION; EARLY DETECTION OF CANCER; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; ONCOGENE PROTEINS, FUSION; PATIENT PARTICIPATION; POPULATION SURVEILLANCE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84862276441     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2012.1226     Document Type: Editorial

References (7)

1. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. Six-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004;292(7):821-827. (Pubitemid 39079668)
2. Newcomb LF, Brooks JD, Carroll PR, et al. Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository. Urology. 2010;75(2):407-413.
3. Zaytoun OM, Anil T, Moussa AS, Jianbo L, Fareed K, Jones JS. Morbidity of prostate biopsy after simplified versus complex preparation protocols: assessment of risk factors. Urology. 2011;77(4):910-914.
4. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009;181(3):956-962.
5. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006;98(8):529-534. (Pubitemid 43898816)
6. Williams SB, Salami S, Regan MM, Ankerst DP, Wei JT, Rubin MA, Thompson IM, Sanda MG. Selective detection of histologically aggressive prostate cancer: an Early Detection Research Network prediction model to reduce unnecessary prostate biopsies with validation in the Prostate Cancer Prevention Trial [published online October 17, 2011]. Cancer. doi:10.1002/cncr.26396.
7. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212-236.